Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP1295717.RAJzPMtJqH0Wkip9urRYsRg0QN_yhsGZOHH9qU7E_C5O8130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP1295717.RAJzPMtJqH0Wkip9urRYsRg0QN_yhsGZOHH9qU7E_C5O8130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP1295717.RAJzPMtJqH0Wkip9urRYsRg0QN_yhsGZOHH9qU7E_C5O8130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP1295717.RAJzPMtJqH0Wkip9urRYsRg0QN_yhsGZOHH9qU7E_C5O8130_provenance.
- NP1295717.RAJzPMtJqH0Wkip9urRYsRg0QN_yhsGZOHH9qU7E_C5O8130_assertion description "[Irreversible inhibition of Bruton's tyrosine kinase (BTK) by ibrutinib represents an important therapeutic advance for the treatment of chronic lymphocytic leukemia (CLL).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1295717.RAJzPMtJqH0Wkip9urRYsRg0QN_yhsGZOHH9qU7E_C5O8130_provenance.
- NP1295717.RAJzPMtJqH0Wkip9urRYsRg0QN_yhsGZOHH9qU7E_C5O8130_assertion evidence source_evidence_literature NP1295717.RAJzPMtJqH0Wkip9urRYsRg0QN_yhsGZOHH9qU7E_C5O8130_provenance.
- NP1295717.RAJzPMtJqH0Wkip9urRYsRg0QN_yhsGZOHH9qU7E_C5O8130_assertion SIO_000772 26641137 NP1295717.RAJzPMtJqH0Wkip9urRYsRg0QN_yhsGZOHH9qU7E_C5O8130_provenance.
- NP1295717.RAJzPMtJqH0Wkip9urRYsRg0QN_yhsGZOHH9qU7E_C5O8130_assertion wasDerivedFrom befree-2016 NP1295717.RAJzPMtJqH0Wkip9urRYsRg0QN_yhsGZOHH9qU7E_C5O8130_provenance.
- NP1295717.RAJzPMtJqH0Wkip9urRYsRg0QN_yhsGZOHH9qU7E_C5O8130_assertion wasGeneratedBy ECO_0000203 NP1295717.RAJzPMtJqH0Wkip9urRYsRg0QN_yhsGZOHH9qU7E_C5O8130_provenance.
- befree-2016 importedOn "2016-02-19" NP1295717.RAJzPMtJqH0Wkip9urRYsRg0QN_yhsGZOHH9qU7E_C5O8130_provenance.